News Intercept shares dive after FDA safety alert on liver drug Regulator warns of death risk in patients on higher than recommended dose.
News EU regulator recommends Intercept's potential liver blockbus... Sales forecast to reach $2.6 billion in 2020.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
